한글목차

약제 요약

Immunvaccine이 개발중인 Maveropepimut-S(MVP-S, 구 DPX-Survivac)는 DPX 플랫폼과 암 항원 서바이빈(Survivin)을 결합한 T세포 활성화 면역요법입니다. 생체 내에서 표적 T세포를 생성하는 IMV의 새로운 면역치료제 계열의 선도적 임상 후보물질입니다. DPX-Survivac은 Merck KGaA로부터 전 세계 독점 라이선스를 획득한 서바이빈 기반 항원(Survivin-based antigen)을 사용하여 Depo-Proteins를 사용하며, DepoVax 백신 전달 플랫폼으로 제형화됩니다.

현재 플래티넘 제제 내성 상피성 난소암을 대상으로 한 임상 2상(AVALON)이 진행 중이며, 2025년 8월까지 완료될 예정입니다.

주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 난소암용 DPX-Survivac에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 난소암에서의 DPX-Survivac 개요

• 제품의 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신치료법)

제5장 DPX-Survivac 시장 평가

• 난소암에서 DPX-Survivac의 시장 전망
• 주요 7 시장 분석
  • 주요 7 시장 난소암용 DPX-Survivac의 시장 규모
• 시장 분석 : 국가별
  • 미국의 난소암용 DPX-Survivac의 시장 규모
  • 독일의 난소암용 DPX-Survivac의 시장 규모
  • 영국의 난소암용 DPX-Survivac의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"DPX-Survivac Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about DPX-Survivac for ovarian cancer in the seven major markets. A detailed picture of the DPX-Survivac for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DPX-Survivac for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DPX-Survivac market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

Maveropepimut-S (MVP-S, previously known as DPX-Survivac), being developed by Immunvaccine, is a T cell activating immunotherapy that combines the power of DPX Platform with cancer antigen survivin. It is the lead clinical candidate in IMV's new class of immunotherapies that generates targeted T cells in vivo. By activating survivin-specific killer T cells, maveropepimut-S promotes the destruction of cancer cells and disrupts the fundamental processes of cancer cell production and survival. DPX-Survivac uses Survivin-based antigens in-licensed from Merck KGaA on a worldwide exclusive basis and formulated in the DepoVax vaccine delivery platform.

It is currently being investigated in Phase II clinical trial (AVALON) for the potential treatment of platinum-resistant epithelial ovarian cancer that is estimated to be completed by August 2025.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DPX-Survivac description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on DPX-Survivac regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DPX-Survivac research and development activities in ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DPX-Survivac.
• The report contains forecasted sales of DPX-Survivac for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for DPX-Survivac in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DPX-Survivac Analytical Perspective by DelveInsight

• In-depth DPX-Survivac Market Assessment

This report provides a detailed market assessment of DPX-Survivac for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• DPX-Survivac Clinical Assessment

The report provides the clinical trials information of DPX-Survivac for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DPX-Survivac dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to DPX-Survivac and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DPX-Survivac in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of DPX-Survivac from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DPX-Survivac in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of DPX-Survivac?
• What is the clinical trial status of the study related to DPX-Survivac in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DPX-Survivac development?
• What are the key designations that have been granted to DPX-Survivac for ovarian cancer?
• What is the forecasted market scenario of DPX-Survivac for ovarian cancer?
• What are the forecasted sales of DPX-Survivac in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to DPX-Survivac for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. DPX-Survivac Overview in ovarian cancer

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DPX-Survivac Market Assessment

• 5.1. Market Outlook of DPX-Survivac in ovarian cancer
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DPX-Survivac in the 7MM for ovarian cancer
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DPX-Survivac in the United States for ovarian cancer
  • 5.3.2. Market Size of DPX-Survivac in Germany for ovarian cancer
  • 5.3.3. Market Size of DPX-Survivac in France for ovarian cancer
  • 5.3.4. Market Size of DPX-Survivac in Italy for ovarian cancer
  • 5.3.5. Market Size of DPX-Survivac in Spain for ovarian cancer
  • 5.3.6. Market Size of DPX-Survivac in the United Kingdom for ovarian cancer
  • 5.3.7. Market Size of DPX-Survivac in Japan for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options